Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs
AbstractMicroRNAs (miRs, miRNAs) are regulatory small noncoding RNAs, with their roles already confirmed to be important for post-transcriptional regulation of gene expression affecting cell physiology and disease development. Upregulation of a cancer-causing miRNA, known as oncogenic miRNA, has been found in many types of cancers and, therefore, represents a potential new class of targets for therapeutic inhibition. Several strategies have been developed in recent years to inhibit oncogenic miRNAs. Among them is a direct approach that targets mature oncogenic miRNA with an antisense sequence known as antimiR, which could be an oligonucleotide or miRNA sponge. In contrast, an indirect approach is to block the biogenesis of miRNA by genome editing using the CRISPR/Cas9 system or a small molecule inhibitor. The development of these inhibitors is straightforward but involves significant scientific and therapeutic challenges that need to be resolved. In this review, we summarize recent relevant studies on the development of miRNA inhibitors against cancer. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Nguyen, D.-D.; Chang, S. Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs. Int. J. Mol. Sci. 2018, 19, 65.
Nguyen D-D, Chang S. Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs. International Journal of Molecular Sciences. 2018; 19(1):65.Chicago/Turabian Style
Nguyen, Dinh-Duc; Chang, Suhwan. 2018. "Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs." Int. J. Mol. Sci. 19, no. 1: 65.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.